How Long Do You Do Allergy Shots? Age-Specific Duration Guide

The minimum recommended age for allergy shots is 5 years, as specified in EAACI guidelines and supported by the American Academy of Pediatrics. The age cutoff is based on practical considerations — the ability of a child to communicate symptoms, cooperate with the observation period, and tolerate injections reliably — rather than safety-based concerns. There is no immunological or physiological reason why younger children cannot mount a response to SCIT. In clinical practice, some allergists may begin immunotherapy in children under 5 in exceptional circumstances, particularly for severe Hymenoptera venom allergy. The PAT study by Moller et al. in JACI 2002 enrolled children aged 6 to 14, establishing the strongest evidence base for pediatric SCIT in this age range.

Evidence suggests children may require shorter SCIT courses to achieve durable tolerance, primarily due to greater immune plasticity at younger ages. The PAT study demonstrated meaningful disease modification — including asthma prevention — after a 3-year protocol in children aged 6 to 14, and the protective effect lasted 7 years after stopping. Children who are monosensitized appear to have particularly durable post-treatment benefit compared to monosensitized adults, per Yuan et al. in Otolaryngology — Head and Neck Surgery 2024. That said, current AAAAI guidelines recommend the same 3-year minimum for both children and adults, and the 5-year option remains appropriate for polysensitized pediatric patients with asthma comorbidity.

Allergy shots are generally safe for elderly patients and there is no upper age limit per AAAAI guidelines. A randomized controlled trial by Bozek et al. in 2016 enrolled patients aged 65 to 75 with grass pollen allergic rhinitis and demonstrated significant symptom and medication score reductions with 3 years of SCIT — confirming that older patients can respond effectively to immunotherapy. The main considerations for seniors include assessment of cardiovascular comorbidities (not a contraindication but relevant for monitoring), evaluation of beta-blocker use (a relative contraindication because beta-blockers reduce epinephrine effectiveness if a systemic reaction occurs), and individualized benefit-risk discussion factoring in the shorter remaining lifetime benefit window. Contemporary data from Sturm et al. in Allergy 2021 confirmed that beta-blockers did not significantly increase adverse event rates during venom immunotherapy in a large prospective cohort.

No — allergy shots should not be initiated during pregnancy. The AAAAI and ACAAI practice parameters published by Cox et al. in JACI 2011 are explicit: SCIT should not be started during pregnancy because systemic reactions during the build-up phase could theoretically compromise fetal safety through hypotension or anaphylaxis. However, patients already established on a maintenance dose before becoming pregnant can safely continue their monthly maintenance injections throughout pregnancy. The dose should not be increased during pregnancy. Some allergists may choose to continue maintenance at a slightly reduced dose to minimize systemic reaction risk during the pregnancy. The current recommendation is to complete SCIT before a planned pregnancy or to continue only existing maintenance doses.

The standard protocol duration — 3 to 5 years — applies across all age groups. The practical difference lies in the benefit calculation. A child who completes SCIT at age 10 gains 3 to 12-plus years of post-treatment benefit during a lifetime that may include 60 to 70 more years of allergen exposure — an exceptionally favorable investment. An adult who completes at age 35 gains the same post-treatment benefit window but with fewer remaining decades. A senior who completes at age 70 gains 10 to 15 years of post-treatment benefit, which may significantly improve quality of life but represents a more modest lifetime return on the 3-to-5-year investment. These calculations are one reason why early intervention in children is considered particularly high-value in allergy medicine.

Yes — allergy shots are effective for older adults, and the historical exclusion of seniors from immunotherapy trials has been corrected by more recent evidence. The Bozek et al. randomized trial demonstrated significant symptom and medication score improvements in patients aged 65 to 75 after 3 years of grass SCIT. Immune senescence — the natural decline in immune responsiveness with age — may modestly reduce response rates compared to younger adults, but the clinical benefit remains meaningful. The primary considerations for senior patients are: confirming there are no absolute contraindications (severe uncontrolled asthma, significant cardiovascular instability), assessing beta-blocker use, evaluating whether the patient can sustain the visit schedule, and having an explicit informed consent discussion about the benefit-years calculation and the 3-to-5-year time investment.

Adolescents aged 13 to 17 have the highest SCIT dropout rates of any age group — approximately 60 percent per Kiel et al. in JACI 2013. The primary drivers are unique to adolescent life: school schedules that make weekly clinic visits during the build-up phase logistically challenging, extracurricular commitments (sports, clubs, activities) that compete with appointment times, emerging autonomy and resistance to parent-managed medical schedules, and social self-consciousness about being in treatment. Additionally, adolescents may not have the long-term planning orientation to perceive the value of a 3-to-5-year medical investment. Strategies to improve adolescent adherence include cluster protocols (fewer but longer appointments), after-school shot clinic hours, involving the teenager in the scheduling decision, and clear communication about when benefit is expected to appear.